Study on the Treatment of Anal Fistulas Using Alofisel Versus Fat

Status Not yet recruiting

Clinical Trial Summary

One of the newest and most innovative medicinal approaches is cell therapy. Several clinical trials and experimental investigations have looked into the feasibility of treating CD-related fistulas with stem cells. The current indication for ALOFISEL® (active ingredient: Darvadstrocel) is the treatment of difficult perianal Crohn's fistulas that have not responded well to at least one conventional therapy or biotherapy. This brand-new cell therapy medication is created using amplified allogeneic human adult mesenchymal stem cells from adipose tissue (ADSC). The supplier mandates that two patients be booked for a single dose of ALOFISEL® due to the medication's expensive price-roughly €54,000 for a single dose of 120 million-which cannot be stored once thawed. Only one of the two patients receives therapy; the other serves as the backup patient. By doing this, another "back-up" patient who might receive no care at all is avoided. An developing alternate approach to allogeneic ADSC injection for the treatment of complicated anal fistulas in CD is autologous fat injection. In recent years, autologous fat grafts have been the subject of in-depth research. They are popular because it is simple to get clinical samples (lipoaspirate, adipose tissue), and because there are a lot of ADSCs in adipose tissue. Additionally, ADSCs show strong immunomodulatory and regenerative capacities. We would wish to compare the effectiveness of these two injection kinds on perianal fistulas as part of our care of CD.

Clinical Trial Description

The trial will be made available to patients who are scheduled for perianal surgery with ALOFISEL® or backup (fat injection). The history and signs of perianal fistula will be noted if the patient doesn't object. Two visits that correspond to typical follow-up visits for patients will be noted: Visit following surgery: fistula clinical evaluation, analgesic use, etc. and six months after : clinical assessment, MRI ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05974280
Study type	Observational
Source	Nantes University Hospital
Contact
Status	Not yet recruiting
Phase
Start date	January 2024
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04046913` - The ADDapt Diet in Reducing Crohn's Disease Inflammation	N/A
Recruiting	`NCT05169593` - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy	Phase 4
Recruiting	`NCT06116604` - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting	`NCT05316584` - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy	N/A
Recruiting	`NCT05627128` - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease	N/A
Recruiting	`NCT05294107` - Intestinal Organoids	N/A
Withdrawn	`NCT04349449` - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed	`NCT03058679` - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease	N/A
Completed	`NCT02871635` - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity	Phase 3
Recruiting	`NCT04539665` - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.	N/A
Recruiting	`NCT04266600` - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease	N/A
Recruiting	`NCT03913572` - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed	`NCT03668249` - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed	`NCT03606499` - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Terminated	`NCT04102111` - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease	Phase 2
Recruiting	`NCT04997733` - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal	Phase 3
Recruiting	`NCT05906576` - Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients	Phase 4
Not yet recruiting	`NCT04398836` - Preoperative Nutrition for Crohn's Disease Patients	Phase 3
Not yet recruiting	`NCT04502303` - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study on the Treatment of Anal Fistulas Using Alofisel Versus Fat Autologous Stem Cells — CHAZAM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms